|
|
Canada Communicable Disease Report
Vol. 24 (ACS-4)
15 November 1998
An Advisory Committee Statement (ACS)
Committee to Advise on Tropical Medicine and Travel (CATMAT)*
STATEMENT ON HIGH ALTITUDE ILLNESSES
Adobe
Downloadable Document
(187 KB)
Introduction
Many Canadians travel to recreational areas which are located at high
altitude (> 1,500 m). As altitude increases, the total pressure and
partial pressure of oxygen decreases, resulting in hypoxia which may be
associated with decreased exercise performance, increased ventilation,
and symptoms of lightheadedness, fatigue, altered perceptions, and sleep
disorders. Although the risk increases with altitude, some susceptible
individuals may experience symptoms of altitude-related illness beginning
as low as 2,500 m.
Specific altitude illnesses include acute mountain sickness (AMS), high-altitude
pulmonary edema (HAPE), high-altitude cerebral edema (HACE), and a number
of other medical problems (Table 1). Travel to altitiude
may also aggravate underlying illnesses, particularly cardiopulmonary
diseases. On the basis of increasing risk of health problems, altitudes
can be subclassified into high (1,500 to 3,500 m), very high (> 3,500
to 5,500 m) and extreme (> 5,500 m)(1). The risk of altitude
illness increases directly with the rate of ascent and the altitude reached.
Rapid ascent to altitudes > 5,500 m, even for brief exposures, may
be associated with severe or fatal illness. The barometric pressure at
5,500 m is one-half of that at sea level. In addition, the temperature
drops an average of 6.5o C per 1,000 m of elevation and penetration
of ultraviolet (UV) light increases about 4% per 300 m gain in altitude
(1). The combination of cold and hypoxia enhances the
risk of cold injuries and altitude problems. The extra UV penetration
increases the risk of sunburn, skin cancer, and snow-blindness. Furthermore,
in the absence of wind, the reflection of sunlight on flat glaciers can
lead to intense radiation with a paradoxical temperature elevation of
up to 40o C. Heat exhaustion or dehydration may thus go unrecognized.
Acclimatization is the process by which climbers gradually adjust to hypoxia.
This enhances performance and ultimately survival at extreme altitudes.
Table 1 Potential medical problems associated with
high-altitude ascent(1)
Table 1
Potential medical problems associated with high-altitude ascent(1)
|
Acute hypoxia+
|
Acute mountain sickness+
|
High-altitude cerebral edema+
|
High-altitude pulmonary edema+
|
Cerebrovascular syndromes
|
Peripheral edema
|
Retinopathy+
|
Thromboembolism
|
Sleep disorders and periodic breathing+
|
High-altitude pharyngitis and bronchitis
|
Ultraviolet exposure and keratitis
(snowblindness)
|
Exacerbation of pre-existing illness
|
+ Covered in this statement
|
Recommendations
Table 2 presents evidence-based medicine categories
for the strength and quality of the evidence for the recommendations that
follow.
Acute Hypoxia
Acute profound hypoxia may occur during rapid ascent, or when there
is an abrupt decline in oxygenation. The latter may be due to overexertion,
carbon monoxide poisoning, pulmonary edema, sleep apnea, or failure of
the system used to deliver oxygen. Symptoms include fatigue, weakened
sensory perceptions, vertigo, sleepiness, hallucinations, and ringing
in the ears. The ultimate consequence of acute hypoxia is loss of consciousness,
which occurs in the non-acclimatized person at an arterial oxygen saturation
(SaO2) of 40% to 60% or an arterial PO2 of < 30 mm Hg(1).
Table 2 Strength and quality of evidence summary
sheet(2)
Categories for the strength of each recommendation
|
CATEGORY
|
DEFINITION
|
A
|
Good evidence to support a recommendation for use.
|
B
|
Moderate evidence to support a recommendation for use.
|
C
|
Poor evidence to support a recommendation for or against use.
|
D
|
Moderate evidence to support a recommendation against use.
|
E
|
Good evidence to support a recommendation against use.
|
Categories for the quality of evidence on which recommendations
are made
|
GRADE
|
DEFINITION
|
I
|
Evidence from at least one properly randomized, controlled trial.
|
II
|
Evidence from at least one well designed clinical trial without
randomization, from cohort or case-controlled analytic studies,
preferably from more than one centre, from multiple time series,
or from dramatic results in uncontrolled experiments.
|
III
|
Evidence from opinions or respected authorities on the basis of
clinical experience, descriptive studies, or reports of expert committees.
|
Recommendations for the treatment of acute hypoxia
-
Treatment of acute hypoxia includes immediate administration of
oxygen, rapid pressurization, or descent(3) (A II).
-
Whenever possible, secondary causes of hypoxia such as overexertion,
apnea, or failure of the system to deliver oxygen should also be corrected
(B II).
-
Hyperventilation should be considered; it may increase the minute
ventilation and thereby increase the amount of time of consciousness
(B II).
Acute Mountain Sickness
Table 3 summarizes the 1993 Lake Louise Consensus
Committee definition of AMS. AMS symptoms may be assessed with the
use of a self-administered questionnaire, and supplemented by a clinical
assessment that evaluates changes in mental status, ataxia, and peripheral
edema. AMS is now considered to be primarily due to the body's response
to modest hypoxia and has a different pathophysiology from simple acute
hypoxia, being associated with fluid shifts not seen with hypoxia alone.
In some cases, AMS may occur even with modest increases in altitude. Incidence
of AMS decreases with advancing age(4), and occurs in up to
25% of adults ascending from sea level to 2,000 m(5) and 28%
of children at 2,835 m(6). AMS is unrelated to physical fitness,
weight of luggage carried, gender, or recent respiratory infection.
Table 3 The Lake Louise Consensus Committee definition
of acute mountain sickness(4)
To diagnose AMS, all of criteria 1 to 3 and one of symptoms
a to d are required:
Criteria
1) a recent gain in altitude
2) at least several hours at the new altitude, and
3) the presence of headache
Symptoms
a) gastrointestinal upset (anorexia, nausea, or vomiting)
b) fatigue or weakness
c) dizziness or lightheadedness
d) difficulty sleeping
|
AMS can be classified as mild, moderate or severe based on the symptoms
present(4). The cardinal symptoms of moderate to severe AMS
are headache, fatigue, dizziness, anorexia, nausea, vomiting, dyspnea
on exertion, and ataxia(7). The headache is typically a throbbing
one most pronounced in the bitemporal or occipital areas, worse in the
morning and at night, and aggravated with the Valsalva maneuver. In moderate
to severe AMS, there is relative hypoventilation(8), retention
of fluid(9), raised intracranial pressure(10), impaired
gas exchange, and interstitial edema(11). An early finding
is the lack of diuresis normally observed at high altitude, with a decreased
urine output and fluid retention. This may be related to the failure of
decrease in aldosterone. Alderstoerone usually decreases with ascent but
this may not occur in severe AMS. Furthermore, the renin-angiotensin system
is less suppressed at altitude in persons with AMS compared to those without,
and the glomerular filtration rate is diminished(12). The net
fluid retention and subsequent over-hydration of brain cells, combined
with increased permeability of the blood-brain barrier (vasogenic edema)
leads to increased intracranial pressure in severe AMS, with coma as the
end result. Increased levels of carbon monoxide secondary to the use of
small, windproof shelters or cooking in such confined shelters at high
altitude can aggravate or precipitate AMS.
Differential diagnosis of acute mountain sickness
The differential diagnosis of AMS includes influenza-like viral illness,
alcoholic hangover, exhaustion and dehydration, and high-altitude cerebral
edema.
Recommendation for management of acute mountain sickness
The most important aspect of AMS management is early recognition because
initial clinical presentation does not predict its eventual severity.
Recommendations for the treatment of acute mountain sickness
-
Stop ascent, with rest and acclimatization at the same altitude;
acclimatization may require 12 hours to 4 days (A II).
- Decend immediately if
- there are symptoms of severe AMS: neurologic abnormalities (ataxia
or altered level of consciousness) and/or pulmonary edema (A II),
and/or
- symptoms progress at the same altitude during acclimatization or treatment
(A II).
- Descent to an altitude at least 500 m lower than where the symptoms
began will usually reverse AMS.
- Specific therapeutic drugs
-
Acetazolamide (250 mg orally within 24 hours of onset of symptoms
and 250 mg orally 8 hours later): a carbonic anhydrase inhibitor that
hastens acclimatization and shortens duration of AMS through its action
on acid-base balance(11). It causes renal excretion of
bicarbonate, leading to metabolic acidosis, a compensatory hyperventilation,
and improved oxygenation (A I).
Side effects of acetazolamide include paresthesias, polyuria, nausea,
drowsiness, impotence, and myopia. The taste of carbonated beverages,
including beer, can be altered because the carbon dioxide they contain
can be tasted. Because it is a sulfa drug, acetazolamide is contraindicated
in persons known to be allergic to these compounds. Rarely, acetazolamide
causes crystalluria and bone marrow suppression.
-
Furosemide (80 mg orally twice a day): a diuretic which was found
to be useful in treatment in one case series, but cannot be recommended
without further evaluation(9) (C III).
-
Dexamethasone (4 mg to 8 mg intravenous, intramuscular, or oral loading
dose followed by 4 mg every 6 hours): a steriod that is effective
for moderate AMS(13-15) and leads to marked improvement
within 12 hours, but should be reserved for patients with progressive
neurologic symptoms, or ataxia. Discontinuation of dexamethasone without
descent usually leads to recurrence of symptoms, so it should not
be used alone to treat AMS. It should be used either in combination
with descent or with acetazolamide to hasten acclimatization (A
I).
-
Hyperbaric therapy
The main goal of hyperbaric therapy is to simulate descent and to
give symptomatic improvement within a few hours as a temporizing measure
while awaiting descent. Lightweight (7 kg) manual air-pump, fabric
pressure bags (Gamow bags) are now effectively used on mountaineering
expeditions and in mountain clinics as temporizing measures. Two randomized
controlled trials have examined the effect of short-term treatment
of AMS at high altitude. The first study demonstrated that the use
of hyperbaric therapy was of similar efficacy to oxygen therapy(16).
The other showed that hyperbaric therapy was superior to bed rest(17).
However, neither study showed a benefit compared to controls after
12 hours. Therefore, this treatment should be considered as a temporizing
measure only, and descent is still the treatment of choice (A I).
- Symptomatic treatments that may be considered include
Analgesics
-
Ibuprofen (single 400 mg oral dose) was shown to be superior to placebo
in reducing high-altitude headache severity and increased speed of
relief among military service personnel going from base camp at sea
level to 5,000 m altitudes in a randomized controlled crossover design
trial(18). It is postulated that prostaglandin-mediated
increase in cerebral microvascular permeability may contribute to
the pathophysiology of AMS , and treatment with prostaglandin synthetase
inhibitors may reduce this response. The main potential side effects
of ibuprofen are gastrointestinal bleeding and easy bruising (A
I).
-
Acetaminophen: some experts recommend this analgesic for mild headaches
(C III).
-
Sumatriptan, a selective agonist of 5-hydroxytryptamine receptor
used for migraine headaches, was shown to be inferior to ibuprofen
in a randomized controlled trial(18) and is not recommended
(E I).
Prochlorperazine (5 mg to 10 mg intramuscularly) or promethazine
(50 mg by rectum or orally) may be beneficial for nausea and vomiting
(B III).
-
Sedatives and alcohol should be avoided and exertion should be minimized
(D III).
-
Low-flow oxygen (if available) at 0.5 L/min to 1 L/min at night
is useful especially for high-altitude headaches and is suggested
for mild AMS(2) (A I).
Note: Anecdotal reports from experienced physicians and climbers
suggest that descent is more effective and oxygen should not be used alone
for moderate or severe AMS.
Prevention of Acute Mountain Sickness
General measures
- The safest method is graded ascent(4). Graded ascent means
that climbers, especially persons without altitude experience, should
-
avoid rapid ascent to sleeping altitudes > 3,000 m
-
spend 2 to 3 nights at 2,500 m to 3,000 m before going higher
-
spend an extra night for acclimatization every 600 m to 900 m if
continuing ascent.
Day trips to higher altitude, with a return to lower altitude for
sleep, aid in acclimatization. A general rule of thumb is that >
3,000 m, each night should be spent not > 300 m above the last,
with a rest day (2 nights at the same altitude) every 2 or 3 days
(B III).
-
Alcohol and sedative-hypnotics should be avoided (D III).
-
A high carbohydrate diet (> 70%) reduced AMS symptoms by 30%
in soldiers taken quickly to near the summit of Pike's Peak (4,300
m) and should be considered as an adjunctive preventative measure(20,21)
(A II).
-
Overexertion (activities involving more than walking around or tending
to camp chores) contributes to illness, and should be avoided.
Mild exercise aids in acclimatization but severe heavy exercise should
be avoided (B III).
Pharmacologic measures
- Specific Preventative Drugs
-
Acetazolamide: a carbonic anhydrase inhibitor (see under Treatment
of AMS above) which, in numerous randomized controlled studies,
has been shown to be effective in preventing AMS in persons transported
rapidly to altitudes of 4,000 m to 4,500 m (22-28).
Small doses of 125 mg to 250 mg orally twice a day, starting 24 hours
prior to ascent, have been reported to be as effective as higher doses(29).
One 500 mg tablet of sustained release acetazolamide taken orally
every 24 hours has also been shown in one randomized trial to be of
equivalent effectiveness with fewer side effects due to lower peak
serum levels(30). Acetazolamide should be continued only
for the first 2 days at high altitude while acclimatization occurs
(A I).
Indications: rapid ascent (<= 1 day) to altitudes > 3,000 m,
a rapid gain in sleeping altitude (e.g. moving camp from 4,000 m to
5,000 m in one day), and a past history of AMS or HAPE (A I).
The side effects of acetazolamide have been discussed (see under Treatment
of AMS above) and should be considered.
-
Methazolamide: one randomized trial involving 20 climbers (19 males,
one female) showed equal efficacy of this carbonic anhydrase inhibitor
(150 mg orally once a day, starting 1 week prior to ascent) in preventing
AMS symptoms. Compared with acetazolamide, fewer patients developed
paraesthesias on methazolamide(31) (B II).
-
Spironolactone (25 mg orally 4 times a day): one randomized study
showed spironolactone to be of similar efficacy to acetazolamide,
but this has not been confirmed(26) (B II).
-
Dexamethasone: many randomized studies have shown dexamethasone to
have similar efficacy to acetazolamide in reducing the incidence of
AMS(24, 32-36). One randomized trial of 32 healthy backpackers
climbing at between 3,650 m to 4,050 m on the Sierra Nevada Mountains
found that the combination of dexamethasone acetate (4 mg orally four
times a day) with acetazolamide (250 mg orally twice a day) was superior
to dexamethasone or acetazolamide alone(37). In another
study, a dose as low as 4 mg dexamethasone every 12 hours was effective
in reducing AMS symptoms(34). However, because most cases
only have mild AMS, the availability of an effective alternative in
acetazolamide, and the potential for rebound and other serious side
effects from dexamethasone, we recommend restricting the use of dexamethasone
only for treatment of AMS, or for prophylaxis as necessary in intolerant
persons or those allergic to acetazolamide (A I).
-
Nifedipine: in the only randomized trial for AMS prevention, this
calcium channel inhibitor was shown to be beneficial in lowering the
pulmonary arterial pressures during rapid ascent to 4,559 m, but had
no effect on gas exchange and symptoms of AMS(38). Although
nifedipine may be of help in HAPE, it has not been found to be helpful
in AMS (D I).
High-Altitude Cerebral Edema
HACE is usually recognized when a person with AMS or HAPE develops symptoms
of encephalopathy. HACE can be viewed as the extreme end of the spectrum
of AMS, and it rarely occurs without HAPE(39). It is characterized
by ataxia, extreme lassitude, and altered level of consciousness in the
form of confusion, impaired thinking, drowsiness, stupor, and coma. Other
possible symptoms and signs include cyanosis or grayish colour, headaches,
nausea and vomiting, hallucinations, cranial nerve palsy, hemiparesis,
hemiplegia, seizures, retinal hemorrhages, and focal neurologic
signs. Examination of blood gases or pulse oximetry shows severe hypoxemia.
A chest x-ray usually reveals signs of pulmonary edema. Progression to
HACE from mild AMS varies from 12 hours to the more common duration of
between 1 and 3 days. The pathophysiologic mechanisms underlying HACE
are similar to those of AMS and result in cerebral edema and raised intracranial
pressure, but are more pronounced(40).
Recommendations for the treatment of high-altitude cerebral
edema
-
Early recognition is most important in the treatment of HACE.
In order to prevent death, descent must be undertaken as soon
as ataxia or altered level of consciousness begins (A II).
-
Hyperbaric therapy (Gamow bag) combined with oxygen should be started
if descent can not be initiated immediately. If oximetry is available,
the oxygen delivered should be titrated to keep the SaO2 at > 90%.
-
Dexamethasone (4 mg to 8 mg intravenous, intramuscular, or oral
loading dose followed by 4 mg every 6 hours), and oxygen (2 L/min
to 4 L/min given by mask or nasal cannula) have also been shown to
be beneficial in addition to descent (A II).
-
The comatose patient
-
A secure airway should be ensured and the bladder may need drainage.
Other mangement components include intubation and hyperventilation,
and careful use of diuretics such as furosemide (B III).
-
There are no controlled trials on the use of steroids in the setting
of coma, but there is anecdotal evidence of good response if started
early in the course of HACE (C III), but a poor response if
started after unconsciousness has set in (D III).
-
Data to support the use of mannitol, saline, or urea for coma are
limited (C III).
Coma may persist for days, even with descent to lower altitude, and
other causes need to be ruled out if this occurs.
Prevention of high-altitude cerebral edema
The prevention of HACE is the same as for AMS. The non-fatal complications
may last for several weeks.
High-Altitude Pulmonary Edema
HAPE, described as a unique clinical syndrome in 1960(41),
is the most common cause of fatality due to high altitude. Up to 20 deaths
are reported annually(42). The incidence of this condition
varies with the rate of ascent, altitude reached, temperature, physical
exertion, use of sleeping pills, and other factors. Whereas 1 in
10,000 skiers in the Rocky Mountains (maximum altitude 3,500 m) develop
HAPE(43), up to 1.6% of trekkers to Mount Everest base camp
at 5,150 %m, 3% of adults trekking in Peru at 3,782 m(44),
and 5.2% of Swiss climbers at 4,559 m(45) developed it. Furthermore,
up to 15% of Indian soldiers develop this syndrome when airlifted from
sea level to altitudes between 3,500 m and 5,500 m(10). Younger
persons and men may be more susceptible(42,44). Persons with
HAPE tend to have a low hypoxic ventilatory drive and a raised pulmonary
vasoconstrictor response to hypoxia(46).
HAPE usually occurs within 2 to 4 days of ascent to altitudes > 2,500
m, most commonly on the second night. The earliest symptoms may include
persistent cough, decreased exercise performance, and increased recovery
time from exercise. Other common symptoms include fatigue, weakness, shortness
of breath on exertion, and the signs of AMS (headache, anorexia, lassitude).
As the condition progresses, dry cough, central and peripheral cyanosis,
tachycardia, and tachypnea occur at rest. The mortality rate is affected
by many variables, especially prompt diagnosis and treatment.
Differential diagnosis of high-altitude pulmonary edema
The differential diagnosis of HAPE includes: pneumonia, pulmonary embolism,
pulmonary infarct, and hyperactive airway disease. In addition, HAPE may
be complicated by super-infection, cerebral edema, pulmonary thrombosis,
frostbite, or trauma from pressure points during immobilization .
Laboratory findings for high-altitude pulmonary edema
Laboratory findings for HAPE include: mild elevation of hematocrit and
hemoglobin, mild elevation of the white blood cell count, and elevated
creatinine phosphokinase levels. Arterial blood gases reveal respiratory
alkalosis and severe hypoxemia. Chest x-ray findings are consistent with
non-cardiogenic pulmonary edema (patchy bilateral interstitial and air
space infiltrate with prominence of the lower lobes).
HAPE is a non-cardiogenic form of pulmonary edema. Although the mechanism
of HAPE is unknown, pulmonary hypertension is always present, and is usually
accompanied by a high protein permeability leak and normal left ventricular
function.
Recommendations for the treatment of high-altitude pulmonary edema
-
Successful treatment of HAPE requires early recognition. Evacuation
to a lower altitude is critical (A II).
For mild HAPE, early descent of only 500 to 1,000 m leads to rapid
recovery. Affected individuals may be able to re-ascend slowly 2 to
3 days later.
-
High-flow oxygen, if available, delivered by face mask or nasal
cannulae can be lifesaving(1) (A II).
In some high-altitude situations, bed rest with oxygen may be enough
for mild HAPE (symptoms only on strenuous activity) if frequent observations
are made to ascertain that clinical improvement is occurring(47).
-
Exertion should be minimized. The patient should be warmed to avoid
cold stress which may elevate the pulmonary arterial pressures (B
III).
-
Positive pressure masks have recently been shown to improve gas exchange,
but should not replace descent(48) (B II).
- Medications play only a small secondary role in the management of
HAPE, because of effective results of descent and treatment with oxygen.
Drug therapy should be considered only as an adjunct to these two modalities
and not as a replacement.
-
Nifedipine (30 mg slow-release capsule orally every 12 to 24 hours
or 10 mg sublingually repeated as necessary) reduces pulmonary vascular
resistance, and pulmonary arterial pressures(49) and should
be considered for adjunctive therapy (B III).
-
Nitric oxide: in a recent randomized controlled trial, inhalation
of 40 ppm of nitric oxide was shown to produce a significant decrease
in mean systolic pulmonary-artery pressure and improve arterial oxygenation
in subjects who were prone to HAPE, but not in those who were resistant
to this condition(50) (B I).
This form of therapy should also be considered as adjunctive to descent
in at risk individuals. However, it may be impractical to administer,
e.g. in skiers.
-
Furosemide (80 mg either intravenously or orally every 12 hours,
with 15 mg of intravenous morphine sulphate added to the first dose):
this treatment remains controversial. One study suggested that it
improved diuresis and clinical status(9). A subsequent
report indicated adverse effects of furosemide in subjects brought
to 5,340 m on Mount Logan(51). Thus, more research is needed
with furosemide prior to recommendation (C III).
-
Morphine: morphine reduces dyspnea, improves oxygenation and comfort
and reduces the heart and respiratory rates. However, concerns have
been raised about the respiratory depression, hypovolemia, and hypotension
that may occur with this therapy combined with furosemide(52)
(C III).
-
After descent, ongoing treatment for severe cases of HAPE consists
of bed rest, and administration of oxygen to maintain SaO2 at >
90%. Most patients recover rapidly with this simple form of therapy,
and intubation and ventilation are rarely needed. Pneumonia should
be treated with antibiotics. Patients may be discharged when there
is clinical improvement, and an arterial PO2 of 60 mm Hg or SaO2 >
90%. They should be warned to resume normal activities slowly(1).
Advice about prevention should also be given (see below).
Prevention of high-altitude pulmonary edema
The same preventive measures as for AMS apply, i.e. graded ascent, slow
acclimatization, low sleeping altitudes, and avoidance of alcohol and
sleeping pills. In addition, overexertion should be avoided, especially
during the first 2 days at altitude.
-
Clinical experience (but no studies) suggests that acetazolamide
may prevent HAPE in persons with a history of recurrent episodes,
especially in children (53) (C III).
-
In one randomized controlled clinical trial, nifedipine (20 mg of
slow-release capsule orally every 8 hours) prevented HAPE in subjects
with a history of repeated episodes who rapidly ascended (within 22
hours) from a low altitude to 4,559 m(54). However,
use of the drug in this fashion is limited because of potentially
harmful side effects including hypotension, headache, nausea, vomiting,
fatigue, dizziness, and pedal edema. Nifedipine should thus
be restricted for use in persons with known susceptibility to HAPE
who nevertheless go to altitudes where supplemental oxygen supplies
and opportunities for descent may be limited(55) (B
I).
Such persons should be warned that in no way does nifedipine replace
graded ascent, and slow acclimatization. Descent should be immediate
if symptoms occur.
-
Individuals who have experienced HAPE should have a cardiac assessment
to rule out undetected cardiovascular conditions (C III).
Table 4 summarizes the key evidence-based medicine
recommendations for each of AMS, HACE, and HAPE.
High-Altitude Sleep Disturbance and Periodic Breathing
Normal sleep is often impairmed at high altitudes. At about 3,048 m,
some individuals will report poor sleep while the majority of persons
sleeping > 4,300 m have marked sleep disturbance(56,57).
In a study of six men during 2 nights at sea level and four non consecutive
nights at 4,301 m at the high altitude, all had disturbed sleep
as measured by sleep electroencephalogram(58). This was characterized
by a significant decrease in sleep stages three and four, and a trend
toward more time spent awake. The men complained of poor sleep but there
was only a small reduction in total sleep time. Five also had periodic
breathing, but arousals from sleep were not always associated with this
breathing pattern. The mechanism of arousal is not certain, but may be
related to hypoxia.
Periodic breathing occurs mainly at night, and is characterized by hyperpnea
followed by apnea. Persons with a high hypoxic ventilatory response (HVR)
have higher rates of periodic breathing(59), while persons
with low HVR may have periods of extreme hypoxemia during sleep that are
unrelated to periodic breathing(61-63). There is evidence that
arousal is protective in preventing severe oxygen deprivation(63-65).
Table 4 Evidence-based management of altitude sickness
|
Acute Mountain Sickness
|
High-Altitude Cerebral Edema
|
High-Altitude Pulmonary Edema
|
MODALITY
|
Prevent
|
Treat
|
Prevent
|
Treat
|
Prevent
|
Treat
|
Descent
|
-
|
A II
|
-
|
A II
|
-
|
A II
|
Hyperbaric therapy
|
-
|
A I*
|
-
|
-
|
-
|
|
Oxygen
|
-
|
A I*
|
-
|
A II*
|
-
|
A II+
|
THERAPEUTIC DRUGS
|
|
|
|
|
|
|
Acetazolamide
|
A I
|
A I+
|
A I
|
-
|
C III
|
|
Methazolamide
|
B II
|
-
|
B II
|
-
|
-
|
|
Spironolactone
|
B II
|
-
|
B II
|
-
|
-
|
|
Furosemide
|
-
|
C III
|
-
|
B III*
|
-
|
C III
|
Dexamethasone
|
A I
*****
|
A I**
|
A I
*****
|
A II*
|
-
|
|
Nifedipine
|
D I
|
-
|
D I
|
-
|
B I
|
A II*
|
SYMPTOMATIC
TREATMENTS
|
|
|
|
|
|
|
Analgesics
|
|
|
|
|
|
|
Ibuprofen
|
-
|
A I***
|
-
|
-
|
-
|
-
|
Acetaminophen
|
-
|
C III***
|
-
|
-
|
-
|
-
|
Anti-emetics
|
|
|
|
|
|
|
Prochloperazine
|
-
|
C III****
|
-
|
-
|
-
|
-
|
Promethazine
|
-
|
C III****
|
-
|
-
|
-
|
-
|
* Must be used as temporizing measure while awaiting descent or
in addition to descent only
** Use with descent or in combination with acetazolamide only
+ Must be given within early (< 24 hours) of mild symptoms: descent
mandatory if symptoms progress
***For high-altitude headaches
****For nausea and vomiting
*****Suggest restrict for treatment alone or for prophylaxis in
at risk persons who are intolerant or allergic to acetazolamide
|
Prevention and treatment of high-altitude sleep disorders
-
Acetazolamide (125 mg orally at bedtime) has been shown to decrease
periodic breathing and apnea, improve oxygenation compared to placebo
and almitrine, and is safe for use as a sleeping aid(61)
with consideration of the side effects previously discussed (see under
Treatment of AMS above) (A I).
-
Temazepam (10 mg orally): a short-acting benzodiazepine that has
also been recently shown to be superior to placebo in decreasing the
number and severity of changes in saturation during sleep and improving
the quality of sleep(66) (A 1).
This was achieved without a significant drop in mean arterial saturation
values during sleep that may have been anticipated with the longer
acting benzodiazepines.
High-Altitude Retinal Hemorrhage
Retinal hemorrhages are very common > 5,200 m(67-69).
These are not necessarily related to AMS and are more related to hypoxemia.
They are symptomatic only if found over the macula. While retinal haemorrhages
may lead to blindness, the majority resolve on descent within 7 to 14
days. Although there is no evidence that the location of a hemorrhage
will be the same on repeat ascent to high altitude, most experts would
consider this to be a contraindication for future ascents. Hemorrhages
not affecting vision are not known to have any clinical significance and
do not warrant descent. Hemorrhages have been induced by strenuous exercise
which increases blood pressure and decreases the arterial oxygen saturation
levels(67). Below 5200 m, hemorrhages are more likely due to
high-altitude illnesses and these should be managed according to the syndrome
involved.
References
-
Hackett PH, Roach RC. High altitude medicine. In: Auerbach
P, ed. Wilderness medicine: management of wilderness and environmental
emergencies. Third ed. St. Louis MO: Mosby, 1995:4.
-
MacPherson DW. Evidence-based medicine. CCDR 1994;20:145-47.
-
Bärtsch P, Baumgartner RW, Waber U et al. Comparison of carbon-dioxide-enriched,
oxygen-enriched, and normal air in treatment of acute mountain sickness.
Lancet 1990;336:772-75.
-
Roach R, Bärtsch P, Oelz O et al. The Lake Louise acute mountain
sickness scoring system. In: Sutton J, Houston G, Coates G, eds.
Hypoxia and molecular biology. Burlington VT: Queen City Press
1993:272-74.
-
Montgomery AB, Mills J, Luce JM. Incidence of acute mountain
sickness at intermediate altitude. JAMA 1989;261:732-34.
-
Theis MK, Honigman B, Yip R et al. Acute mountain sickness in
children at 2835 meters. Am J Dis Child 1993;147:143-45.
-
Wright AD. Prevention of acute mountain sickness. J Clin
Pharm Ther 1987;12:267-8. Editorial.
-
King A, Robinson S. Ventilation response to hypoxia and acute
mountain sickness. Aerosp Med 1972;43:419-21.
-
Singh I, Kapila C, Khanna P et al. High altitude pulmonary edema.
Lancet 1965;1:229-34.
-
Singh I, Khanna P, Srivastava M et al. Acute mountain sickness.
N Engl J Med 1969;280:175-218.
-
Grissom CK, Roach RC, Sarnquist FH et al. Acetazolamide in the
treatment of acute mountain sickness: clinical efficacy and effect
on gas exchange. Ann Intern Med 1992;116:461-65.
-
Bärtsch P, Shaw S, Franciolli H et al. Atrial natriuretic peptide
in acute mountain sickness. J Appl Physiol 1988;65:1929-37.
-
Hackett PH, Roach RC, Wood RA et al. Dexamethasone for prevention
and treatment of acute mountain sickness. Aviat Space Environ
Med 1988;59:950-54.
-
Ferrazzini G, Maggiorini M, Kriemler S et al. Successful treatment
of acute mountain sickness with dexamethasone. Br Med J (Clin
Research Ed) 1987;294:1380-82.
-
Levine BD, Yoshimura K, Kobayashi T et al. Dexamethasone in the
treatment of acute mountain sickness. N Engl J Med 1989;321:1707-13.
-
Kasic JF, Yaron M, Nicholas RA et al. Treatment of acute mountain
sickness: hyperbaric versus oxygen therapy. Ann Emerg Med 1991;20:1109-12.
-
Bärtsch P, Merki B, Hofstetter D et al. Treatment of acute mountain
sickness by simulated descent: a randomised controlled trial.
Br Med J 1993;306:1098-101.
-
Broome JR, Stoneham MD, Beeley JM et al. High altitude headache:
treatment with ibuprofen. Aviat Space Environ Med 1994;65:19-20.
-
Burtscher M, Likar R, Nachbauer W et al. Ibuprofen versus sumatriptan
for high-altitude headache. Lancet 1995;346:254-55. Letter.
-
Hansen J, Hartley L, Hogan R. Arterial oxygen increased by high-carbohydrate
diet at altitude. J Appl Physiol 1972;33:441-45.
-
Consolazio CF, Matoush LO, Johnson HL et al. Effects of a high-carbohydrate
diets on performance and clinical symptomatology after rapid ascent
to high altitude. Fed Proc 1969;283:937-43.
-
Forwand SA, Landowne M, Follansbee JN et al. Effect of acetazolamide
on acute mountain sickness. N Engl J Med 1968;279:839-45.
-
Bradwell AR, Coote JH. The BMRES 1984 Medical Research Expedition
to the Himalayas. Postgrad Med J 1987;63:165-67.
-
Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone
use versus placebo to prevent acute mountain sickness on Mount Rainier.
West J Med 1991;154:289-93.
-
McIntosh IB, Prescott RJ. Acetazolamide in prevention of acute
mountain sickness. J Int Med Res 1986;14:285-87.
-
Jain SC, Singh MV, Sharma VM et al. Amelioration of acute mountain
sickness: comparative study of acetazolamide and spironolactone.
Int J Biometeorol 1986;30:293-300.
-
Larson EB, Roach RC, Schoene RB et al. Acute mountain sickness
and acetazolamide: clinical efficacy and effect on ventilation.
JAMA 1982;248:328-32.
-
Greene MK, Kerr AM, McIntosh IB et al. Acetazolamide in prevention
of acute mountain sickness: a double-blind controlled cross-over study.
Br Med J (Clin Research Ed) 1981;283:811-13.
-
Meyer BH. The use of low-dose acetazolamide to prevent mountain
sickness. S Afr Med J 1995;85:792-93. Letter.
-
Anonymous. Acetazolamide in control of acute mountain sickness.
Lancet 1981;1:180-83.
-
Wright AD, Bradwell AR, Fletcher RF. Methazolamide and acetazolamide
in acute mountain sickness. Aviat Space Environ Med 1983;54:619-21.
-
Johnson TS, Rock PB, Fulco CS et al. Prevention of acute mountain
sickness by dexamethasone. N Engl J Med 1984;310:683-86.
-
Ellsworth AJ, Larson EB, Strickland D. A randomized trial of
dexamethasone and acetazolamide for acute mountain sickness prophylaxis.
Am J Med 1987;83(6):1024-30.
-
Rock PB, Johnson TS, Larsen RF et al. Dexamethasone as prophylaxis
for acute mountain sickness. Effect of dose level. Chest 1989;95:568-73.
-
Keller HR, Maggiorini M, Bärtsch P et al. Simulated descent v
dexamethasone in treatment of acute mountain sickness: a randomised
trial. Br Med J 1995;310:1232-35.
-
Montgomery AB, Luce JM, Michael P et al. Effects of dexamethasone
on the incidence of acute mountain sickness at two intermediate altitudes.
JAMA 1989;261:734-36.
-
Zell SC, Goodman PH. Acetazolamide and dexamethasone in the prevention
of acute mountain sickness. West J Med 1988;148:541-45.
-
Hohenhaus E, Niroomand F, Goerre S et al. Nifedipine does not
prevent acute mountain sickness. Am J Respir Crit Care Med 1994;150:857-60.
-
Hackett PH, Roach RC. High altitude medicine. In: Auerbach
P, ed. Wilderness medicine: management of wilderness and environmental
emergencies. Third ed. St. Louis MO: Mosby, 1995:17.
-
Houston C, Dickinson J. Cerebral form of high altitude illness.
Lancet 1975;2:758-61.
-
Houston C. Acute pulmonary edema of high altitude. N Engl
J Med 1960;263:478-80.
-
Hultgren HN. High-altitude pulmonary edema: current concepts.
Annu Rev Med 1996;47:267-84.
-
Sophocles AM, Jr. High-altitude pulmonary edema in Vail, Colorado,
1975-1982. West J Med 1986;144:569-73.
-
Hultgren H, Marticorena E. High altitude pulmonary edema: epidemiologic
observations in Peru. Chest 1978;74:372-76.
-
Maggiorini M, Buhler B, Walter M et al. Prevalence of acute mountain
sickness in the Swiss Alps. Br Med J 1990;301:853-55.
-
Schoene R. Pulmonary edema at high altitude: review, pathophysiology
and update. Clin Chest Med 1985;6:491-507.
-
Marticorena E, Hultgren H. Evaluation of therapeutic methods
in high altitude pulmonary edema. Am J Cardiol 1979;43:307-12
.
-
Schoene R, Roach R, Hackett P et al. High altitude pulmonary
edema and exercise at 4400 meters on Mt. McKinley: effect of expiratory
positive airway pressure. Chest 1985;87:330-33.
-
Oelz O, Maggiorini M, Ritter M et al. Nifedipine for high altitude
pulmonary oedema. Lancet 1989;2:1241-44.
-
Scherrer U, Vollenweider L, Delabays A et al. Inhaled nitric
oxide for high-altitude pulmonary edema. N Engl J Med 1996;334:624-29.
-
Gray G, Bryan A, Frayser R et al. Control of acute mountain sickness.
Aero Med 1971;42:81-84.
-
Hultgren H. Furosemide for high altitude pulmonary edema.
JAMA 1975;234:589-90.
-
Smith L. High altitude illness. JAMA 1977;237:1199. Letter.
-
Bartsch P, Maggiorini M, Ritter M et al. Prevention of high-altitude
pulmonary edema by nifedipine. N Engl J Med 1991;325:1284-89.
-
Reeves JT, Schoene RB. When lungs on mountains leak - studying
pulmonary edema at high altitudes. N Engl J Med 1991;325:1306-07.
Editorial.
-
Nicholson AN, Smith PA, Stone BM et al. Altitude insomnia: studies
during an expedition to the Himalayas. Sleep 1988;11:354-61.
-
Coote J. Sleep at high altitude. In: Cooper R, ed. Sleep.
London: Chapman Hall, 1994:243-264.
-
Reite M, Jackson D, Cahoon R et al. Sleep physiology at high
altitude. Electroencephalogr Clin Neurophysiol 1975;38:463-71.
-
Lahiri S, Maret K, Sherpa M. Dependence of high altitude
sleep apnea on ventilatory sensitivity to hypoxia. Respir Physiol
1983;52:281-301.
-
Hackett P, Roach R. Medical therapy of altitude illness.
Ann Emerg Med 1987;16:980-86.
-
Hackett P, Roach R, Harrison G et al. Respiratory stimulants
and sleep periodic breathing at high altitude. Almitrine versus acetazolamide.
Am Rev Respir Dis 1987;135:896-98.
-
Sutton JR, Houston CS, Mansell AL et al. Effect of acetazolamide
on hypoxemia during sleep at high altitude. N Engl J Med 1979;301:1329-31.
-
Coote J, Tsang G, Baker A et al. Respiratory changes and quality
of sleep in young high altitude dwellers in the Andes of Peru.
Eur J Appl Physiol 1993;66:249-53.
-
Coote JH , Tsang B, Baker A et al. Polycythemia and central sleep
apnoea in high altitude residents of the Andes. J Physiol (Lond)
1993;459:749P.
-
Selvamurthy W, Raju VR, Ranganathan S et al. Sleep patterns at
an altitude of 3500 metres. Int J Biometeorol 1986;30:123-35.
-
Dubowitz G. Effect of temazapam on oxygen saturation and sleep
quality at high altitude: randomized placebo controlled crossover
trial. Br Med J 1998;316:587-89.
-
McFadden D, Houston C, Sutton J et al. High altitude retinopathy.
JAMA 1981;245:581-86.
-
MacLaren RE. Retinal haemorrhage in Himalayan mountaineers.
J R Army Med Corps 1995;141:25-28.
-
Wiedman M, Tabin G. High-altitude retinal hemorrhage as a prognostic
indicator in altitude illness. Int Ophthalmol Clin 1986;26:175-86.
* Members: Dr. K. Kain (Chairman); H. Birk;
M. Bodie-Collins (Executive Secretary); Dr. S.E. Boraston; Dr. H.O. Davies;
Dr. K. Gamble; Dr. L. Green; Dr. J.S. Keystone; Dr. K.S. MacDonald; Dr.
J.R. Salzman; Dr. D. Tessier.
Ex-Officio Members: Dr. E. Callary (HC); R. Dewart (CDC); Dr.
E. Gadd (HC); Dr. C.W.L. Jeanes; Dr. H. Lobel (CDC); Dr. A. McCarthy (DND).
Liasion Representatives: Dr. R. Birnbaum (CSIH); Dr. S. Kalma
(CUSO); Dr. V. Marchessault (CPS); Dr. H. Onyett (CIDS); Dr. R. Saginur
(CPHA); Dr. F. Stratton (ACE); Dr. B. Ward (NACI).
Acknowledgement: CATMAT gratefully acknowledges Dr. G. Gray, Defense
and Civil Institute of Environmental Medicine, and Dr. K.R. Booth, Alberta
Children's Provincial General Hospital, for their contributions to this
statement.
[Canada Communicable
Disease Report]
|